Teleflex Incorporated
TFX
Jodie situation report
Teleflex Incorporated's current read is isolated; its market group is not confirming.
The latest filing is mixed. 0 of 20 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
- Revenue increased 28.9% versus the comparable filing period.
- Operating margin fell 7.8 percentage points.
- Interest expense increased as borrowings used to fund the VI Business acquisition raised the average outstanding debt balance.
- Interest expense rose to $25.7M for the quarter (vs $18.5M prior year); average interest rate on debt was 3.5% (vs 4.2%), with the increase in expense attributed to higher average outstanding debt from borrowings to fund
Invalidation: The isolated read changes if TFX's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind TFX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depended on by
HAEHaemonetics CorporationcompetitorMay 20, 2026 ▾
“Our main competitors in vascular access closure include Terumo BCT, Abbott Laboratories, Cordis, and Teleflex, where we compete primarily based on clinical and economic value, ease of use, workflow improvements and patient satisfaction.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
TFX is currently a Follower in the organic co-movement group Medical Devices. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.